If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Nunzio Pomara, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Psychiatry
  • Treats: Adults
  • Language: English

Positions
Board Certifications
  • American Board of Psychiatry & Neurology - Psychiatry, 1982
Education and Training
  • Fellowship, Wayne State University Medical Center, Geriatric Psychiatry, 1982
  • Residency, Metropolitan Hospital, 1980

Is this your profile?

Edit profile

Nunzio Pomara, MD does not accept insurance.

Nunzio Pomara, MD does not accept insurance.

Interests

pharmacogenetics, Alzheimer's disease, drug-induced cognitive toxicity, late-life depression

Research Summary

A major focus of Dr. Pomara’s research has been to elucidate pharmacokinetic and pharmacodynamic factors that may contribute to individual vulnerability to drug induced cognitive and psychomotor toxicity in the elderly. He has shown that certain variants of the APOE and TOMM40 genes increase risk for drug-induced adverse events unrelated to pharmacokinetic factors and likely reflecting pharmacodynamic mechanisms.

Other important contributions include his early reports of increased activity in the HPA axis associated with both aging and Alzheimer’s disease (AD), as determined by studies of baseline cortisol and dexamethasone response. These results led to the first pilot clinical trial that examined the cognitive effects of the glucocorticoid receptor antagonist, RU486, in AD. Dr. Pomara also provided early evidence of a decreased cortisol response to naltrexone and an elevation in CSF-glutamate in Alzheimer’s patients.

Dr. Pomara additionally presented the first evidence that late life depression, a condition associated with increased risk for AD or prodromal phase, may be accompanied by state-dependent disturbances in central and peripheral metabolism of amyloid-beta, a peptide implicated in AD.

Academic Contact

Academic office

145 East 32nd Street

Fifth Floor, 503

New York, NY 10016

Phone

212-263-5835

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • Depression treatment and A dynamics: A study of Alzheimer s disease risk

    Learn More
  • Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

    Learn More
View All Research Studies (2)

Read All Publications (199)